Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001140361-25-040534
Filing Date
2025-11-05
Accepted
2025-11-05 16:05:19
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 14802
  Complete submission text file 0001140361-25-040534.txt   16551
Mailing Address 333 SOUTH GRAND AVENUE 28TH FLOOR LOS ANGELES CA 90071
Business Address 333 SOUTH GRAND AVENUE 28TH FLOOR LOS ANGELES CA 90071 (213) 830-6300
Oaktree Capital Group Holdings GP, LLC (Filed by) CIK: 0001403525 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address BIOPOLE ROUTE DE LA CORNICHE 3B EPALINGES V8 1066
Business Address BIOPOLE ROUTE DE LA CORNICHE 3B EPALINGES V8 1066 41 21 653 02 00
ADC Therapeutics SA (Subject) CIK: 0001771910 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91517 | Film No.: 251453857
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)